Insulet (PODD) Cash & Equivalents Growth (1y) (2011 - 2026)
Insulet (PODD) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 157.80 Bn | 151.14 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 115.54 Bn | 112.66 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 103.44 Bn | 95.27 Bn | 5.76 Bn | -7.50% |
| 4 | Boston Scientific | 72.38 Bn | 71.17 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 49.76 Bn | 46.09 Bn | 1.29 Bn | -22.13% |
| 6 | Dexcom | 29.53 Bn | 28.42 Bn | 750.30 Mn | 23.57% |
| 7 | GE HealthCare Technologies | 29.51 Bn | 27.44 Bn | 1.98 Bn | -7.71% |
| 8 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 20.15% |
| 9 | Steris | 20.69 Bn | 20.27 Bn | 697.10 Mn | 156.03% |
| 10 | Insulet | 10.61 Bn | 10.13 Bn | 529.10 Mn | -62.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.56% |
| Dec 31, 2025 | -24.89% |
| Sep 30, 2025 | -16.09% |
| Jun 30, 2025 | 36.61% |
| Mar 31, 2025 | 70.81% |
| Dec 31, 2024 | 35.39% |
| Sep 30, 2024 | 31.69% |
| Jun 30, 2024 | 24.38% |
| Mar 31, 2024 | 21.02% |
| Dec 31, 2023 | 4.37% |
| Sep 30, 2023 | -5.07% |
| Jun 30, 2023 | -6.84% |
| Mar 31, 2023 | -12.53% |
| Dec 31, 2022 | -14.77% |
| Sep 30, 2022 | -15.71% |
| Jun 30, 2022 | -17.08% |
| Mar 31, 2022 | -13.54% |
| Dec 31, 2021 | -12.74% |
| Sep 30, 2021 | 2.21% |
| Jun 30, 2021 | 9.69% |